Document Detail


Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
MedLine Citation:
PMID:  7491699     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A microangiopathic syndrome was observed in 3 of 14 (21%) patients receiving cyclosporine and methylprednisolone (CSA-MP) for graft-versus-host disease (GVHD) prophylaxis between January 1991 and June 1992 at our center. The syndrome consisted of neurological abnormalities, arterial hypertension, intravascular hemolysis with red cell fragmentation, and a drop in platelet counts after allogeneic bone marrow transplantation (BMT) for hematological malignancy, and it occurred around day 50 after BMT. Treatment with plasma exchanges against fresh-frozen plasma resulted in a decrease of serum lactate dehydrogenase and an improvement of neurological symptoms. We compared CSA-MP patients retrospectively with patients who had received cyclosporine and methotrexate (CSA-MTX) for GVHD prophylaxis (n = 70) at our institution. All patients in both groups engrafted. Day 100 survival (80% vs. 79%) and transplant-related mortality (16% vs. 14%) were identical in the two groups. CSA-MP patients had significantly more acute GVHD II-IV (57% vs. 17%, P < 0.01). Arterial hypertension (P < 0.01) and neurological symptoms (P < 0.01) were significantly more frequent in the CSA-MP group. The 11 asymptomatic CSA-MP patients had significantly higher lactate dehydrogenase levels (P < 0.01) and lower platelet counts (P < 0.01) at 40, 60, and 100 days after BMT, which suggests the presence of a subclinical form of microangiopathy. Significantly higher plasma levels of von Willebrand factor antigen in CSA-MP patients on day 50 after BMT (P < 0.05) and absence of large von Willebrand factor multimers on gel electrophoresis in 4 of 13 (31%) CSA-MP patients compared with 0 of 14 (0%) CSA-MTX patients (P < 0.01) further suggest profound endothelial damage in patients receiving CSA-MP for GVHD prophylaxis.
Authors:
P Kalhs; S Brugger; I Schwarzinger; H T Greinix; F Keil; P A Kyrle; P Knöbl; B Schneider; P Höcker; W Linkesch
Related Documents :
14684669 - Cardiovascular and renal risk assessment as a guide for treatment in primary hypertension.
8161259 - Surgical treatment of primary hyperaldosteronism.
2142489 - Improved results with surgical treatment of renovascular hypertension: an individualize...
16256009 - Primary aldosteronism: diagnostic and therapeutic considerations.
16127209 - The evaluation of left ventricular hypertrophy in hypertensive patients with subclinica...
1188529 - Prazosin in the treatment of hypertension: a preliminary study.
16699279 - Infliximab therapy improves the bone metabolism in fistulizing crohn's disease.
11436069 - Lepirudin is a safe and effective anticoagulant for patients with heparin-associated an...
20555049 - Clinical characteristics of people with head nodding in southern tanzania.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Transplantation     Volume:  60     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1996-01-03     Completed Date:  1996-01-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  949-57     Citation Subset:  IM    
Affiliation:
Medical Department I, University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Bone Marrow Transplantation / immunology*
Cyclosporine / adverse effects*,  therapeutic use
Female
Follow-Up Studies
Graft Survival
Graft vs Host Disease / prevention & control*
Hemolysis*
Humans
Hypertension / etiology,  physiopathology*
Immunosuppressive Agents / adverse effects*,  therapeutic use
L-Lactate Dehydrogenase
Male
Methotrexate / therapeutic use
Methylprednisolone / adverse effects*,  therapeutic use
Middle Aged
Nervous System Diseases / etiology,  physiopathology*
Plasmapheresis
Platelet Count
Retrospective Studies
Syndrome
Transplantation, Homologous
Vascular Diseases / chemically induced*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 59-05-2/Methotrexate; 59865-13-3/Cyclosporine; 83-43-2/Methylprednisolone; EC 1.1.1.27/L-Lactate Dehydrogenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Elevated inflammatory cytokine levels in bone marrow graft rejection.
Next Document:  Mycobacterium haemophilum infections in bone marrow transplant recipients.